Rockefeller University
New York, 10065, United States
NCT Number: NCT00772772
The reason for doing this research is that people with kidney disease often suffer from heart disease. Why this happens is not fully known. A possible cause may be high blood levels of a substance made by bacteria called "endotoxin". The blood levels of this substance are high in people with medium-level kidney disease.
We want to know if replacing normal amounts of Vitamin D can help lower the levels of this substance. We also want to know if replacing normal amounts of Vitamin D is associated with other changes that may help heart disease. We hope that our research will help figure out if levels of this substance can be lowered by replacing normal amounts of Vitamin D. Normal subjects are enrolled to have a 'control' set for comparison purposes.
Looking for future studies?
Notify Me50 year–80 year
All sexes
Interventional
Early Phase 1
New York, 10065, United States
Your participation in this study requires:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for Healthy volunteers
Inclusion criteria
for Medium-level Kidney Function volunteers
Exclusion criteria
2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
Other names: Vitamin D
Time frame: baseline and 8 weeks
Endotoxin Activity as measured by the Endotoxin Activity Assay. This measurement was made at baseline and after 8 weeks of therapy with Vitamin D3. The measurement of the assay is unitless. It is not based on an absolute amount of endotoxin, but rather the proportion of the theoretical maximal response of the patient and ranges from 0 (lowest) to 1 (highest).
Time frame: after 8 weeks of vitamin D therapy
Time frame: after 8 weeks of vitamin D therapy
Time frame: after 8 weeks of vitamin D therapy
Time frame: after 8 weeks of vitamin D therapy
25-OH Vitamin D levels were measured in patients with chronic kidney disease at baseline and after 8 weeks of treatment with Vitamin D3 30000 units weekly.
Time frame: after 8 weeks of vitamin D therapy
Rockefeller University
Other
The Effect of Vitamin D3 Repletion in Chronic Kidney Disease Stage 3
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05021835
Cardiovascular Risk, Chronic Disease
Birmingham, Alabama, United States
View Trial DetailsNCT07195747
Arterial Occlusive Diseases, Arteriosclerosis
São Paulo, Brazil
View Trial DetailsNCT05254002
Chronic Disease, Chronic Kidney Disease
Surprise, Arizona, United States
View Trial DetailsNCT02579655
Brain Diseases, Cardiovascular Diseases
Calgary, Alberta, Canada
View Trial Details